Next Article in Journal
Perceptions of Vascular Access for Intravenous Systemic Therapy and Risk Factors for Lymphedema in Early-Stage Breast Cancer—A Patient Survey
Previous Article in Journal
Are Clinical Trial Eligibility Criteria an Accurate Reflection of a Real-World Population of Advanced Non-Small-Cell Lung Cancer Patients?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue 4
10.3747/co.25.3903
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Optimizing Vascular Access for Patients Receiving Intravenous Systemic Therapy for Early-Stage Breast Cancer—A Survey of Oncology Nurses and Physicians

by
N. LeVasseur
1,
C. Stober
2,
K. Daigle
3,
A. Robinson
4,
S. McDiarmid
3,
S. Mazzarello
2,
B. Hutton
5,
A. Joy
6,
D. Fergusson
5,
J. Hilton
1,2,
M. McInnes
7 and
M. Clemons
1,2,5,*
1
Division of Medical Oncology and Department of Medicine, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada
2
The Ottawa Hospital Research Institute, Ottawa, ON, Canada
3
Department of Nursing, The Ottawa Hospital, Ottawa, ON, Canada
4
Division of Medical Oncology, Cancer Centre of Southeastern Ontario, Kingston, ON, Canada
5
Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
6
Department of Oncology, Division of Medical Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
7
Department of Radiology, The Ottawa Hospital, Ottawa, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(4), 298-304; https://doi.org/10.3747/co.25.3903
Submission received: 1 May 2018 / Revised: 2 June 2018 / Accepted: 3 July 2018 / Published: 1 August 2018

Abstract

Background: Despite advances in systemic therapy choices for patients with early-stage breast cancer, optimal practices for intravenous (IV) access remain unknown. That lack of knowledge holds particularly true for the use of central venous access devices (cvads) such as peripherally inserted central catheters (piccs) and implanted vascular access devices (ports). Methods: Using a survey of Canadian oncologists and oncology nurses responsible for the care of breast cancer patients, we evaluated current access practices, perceptions of complications, and perceptions of risk, and we estimated complication rates and evaluated perceived risk factors for lymphedema. Results: Survey responses were received from 25 physicians and 57 oncology nurses. Administration of trastuzumab or an anthracycline was associated with a higher likelihood of a cvad being recommended. Other factors associated with recommendation of a cvad included prior difficult IV access and a recommendation from the chemotherapy nurse. Although the complication rates perceived to be associated with the use of piccs and ports remained high, respondents felt that cvads might improve patient quality of life. Risk factors perceived to be associated with the risk of lymphedema were axillary lymph node dissection, radiation to the axilla, and line-associated infection. Factors known to be unrelated to lymphedema risk (specifically, blood draws and blood pressure measurement) continue to be perceived as posing a higher risk. Conclusions: Despite widespread use of chemotherapy for patients with breast cancer, the type of venous access used for treatment varies significantly, as do perceptions about the risks of cvad use and the risk for lymphedema development. Further prospective studies are needed to identify best-practice strategies.
Keywords: early-stage breast cancer; physician surveys; nurse surveys; vascular access early-stage breast cancer; physician surveys; nurse surveys; vascular access

Share and Cite

MDPI and ACS Style

LeVasseur, N.; Stober, C.; Daigle, K.; Robinson, A.; McDiarmid, S.; Mazzarello, S.; Hutton, B.; Joy, A.; Fergusson, D.; Hilton, J.; et al. Optimizing Vascular Access for Patients Receiving Intravenous Systemic Therapy for Early-Stage Breast Cancer—A Survey of Oncology Nurses and Physicians. Curr. Oncol. 2018, 25, 298-304. https://doi.org/10.3747/co.25.3903

AMA Style

LeVasseur N, Stober C, Daigle K, Robinson A, McDiarmid S, Mazzarello S, Hutton B, Joy A, Fergusson D, Hilton J, et al. Optimizing Vascular Access for Patients Receiving Intravenous Systemic Therapy for Early-Stage Breast Cancer—A Survey of Oncology Nurses and Physicians. Current Oncology. 2018; 25(4):298-304. https://doi.org/10.3747/co.25.3903

Chicago/Turabian Style

LeVasseur, N., C. Stober, K. Daigle, A. Robinson, S. McDiarmid, S. Mazzarello, B. Hutton, A. Joy, D. Fergusson, J. Hilton, and et al. 2018. "Optimizing Vascular Access for Patients Receiving Intravenous Systemic Therapy for Early-Stage Breast Cancer—A Survey of Oncology Nurses and Physicians" Current Oncology 25, no. 4: 298-304. https://doi.org/10.3747/co.25.3903

APA Style

LeVasseur, N., Stober, C., Daigle, K., Robinson, A., McDiarmid, S., Mazzarello, S., Hutton, B., Joy, A., Fergusson, D., Hilton, J., McInnes, M., & Clemons, M. (2018). Optimizing Vascular Access for Patients Receiving Intravenous Systemic Therapy for Early-Stage Breast Cancer—A Survey of Oncology Nurses and Physicians. Current Oncology, 25(4), 298-304. https://doi.org/10.3747/co.25.3903

Article Metrics

Back to TopTop